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Diabetes, one of the incurable pandemic diseases, is charac-
terized by insulin deficiency and insulin resistance, leading to
aberrant homeostasis of glucose, protein, and lipid. Genetic
and environmental factors are the primary causes of diabetes.
International Diabetes Federation estimated that 400 million
people are afflicted with this disease worldwide. However,
current oral antidiabetic agents commonly used in orthodox
medicine have unmet efficacy and undesirable side effects
in patients, which, consequently, can develop cardiovascular
diseases, retinopathy, neuropathy, nephropathy, foot ulcers,
and so forth. Therefore, there is an urgent need for develop-
ment of new remedies for diabetes.
World Health Organization estimates that 80% of
the world population uses complementary and alternative
medicine (CAM) for their primary health care. Therefore,
CAM, includingmedicinal herbs, acupuncture, moxibustion,
and other therapies, is an extraordinary source of diabetes
therapy. The goal of this special issue was to compile and
update the advancement made on basic and clinical research
into CAM for diabetes and its complications.
This special issue accepted 8 manuscripts out of 36
contributions. They cover a wide range of topics, from
preclinical studies to clinical trials on CAM for diabetes and
its complications. One study by K. Raafat and W. Samy titled
“Amelioration of Diabetes and Painful Diabetic Neuropathy
by Punica granatum L. Extract and Its Spray Dried Biopoly-
meric Dispersions” describes the effect of ethanol extract
(Pg), casein/Pg dispersion (F1), chitosan/Pg dispersion (F2),
and gallic acid (GA) on diabetes and related neuropathy in
mice treated with alloxan. They first established the diabetic
mice whose 𝛽 cells were destroyed by alloxan. As expected,
those mice had hyperglycemia. In contrast, Pg, F1, F2, and
GA significantly lowered blood glucose in the mice. Besides,
they also tested the impact of the extracts and compound
on neuropathy. The data showed that Pg, F1, F2, and GA
improved the diabetic neuropathy as evidenced by tail flick
and hot plate latency tests. In the paper entitled “Effects of
Dietary Supplementation with Agaricus sylvaticus Schaeffer
on Glycemia and Cholesterol after Streptozotocin-Induced
Diabetes in Rats,” M. B. Mascaro et al. report the protective
action of the mushroom, A. sylvaticus, as shown by plasma
biochemical parameters and islet structure in streptozotocin-
treated rats. Animal studies indicated that the A. sylvati-
cus crude extract reduced the levels of cholesterol, HDL,
triglycerides, blood sugar, GPT, and alkaline phosphatase but
increased those of transferrin and urea in streptozotocin-
treated rats. Histochemical staining data showed that A. syl-
vaticus suppressed islet atrophy.The overall data imply thatA.
sylvaticus protected against type 1 diabetes probably via hep-
atic and pancreatic regulation. In the paper “Immunomodu-
latory and Antidiabetic Effects of a New Herbal Preparation
(HemoHIM) on Streptozotocin-Induced Diabetic Mice,” J.-
J. Kim et al. studied the beneficial effect of the herbal
preparation (HemoHIM), composed of Angelica gigasNakai,
Cnidium officinaleMakino, and Paeonia japonicaMiyabe, on
type 1 diabetes in streptozotocin-treated mice. They showed
that HemoHIM treatment reduced hyperglycemia, improved
glucose tolerance, and increased blood insulin. Besides, this
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treatment could restore the thymus weight, the number
of blood white cells, blood lymphocytes, splenic CD4 and
CD8 T cells, and ConA-stimulated IFN𝛾 production. Taken
together, the data suggest that HemoHIM exerts antidiabetic
action via regulation of blood glucose homeostasis and
immunity. Another study by Y.-H. Kuo et al., “Caffeamide
36-13 Regulates the Antidiabetic and Hypolipidemic Signs
of High-Fat-Fed Mice on Glucose Transporter 4, AMPK
Phosphorylation, and Regulated Hepatic Glucose Produc-
tion,” reports that caffeamide 36-13 (TS), a caffeic acid amide,
improved hyperglycemia and hyperlipidemia in high fat diet-
fed mice as evidenced by the level of blood glucose, triglyc-
eride, insulin, leptin, and free fatty acid (FFA). Accordingly,
TS diminished abdominal visceral fat, cell size of adipocytes
in visceral fat, and hepatic triglyceride contents. Moreover,
TS increased the level of glucose transporter 4 (GLUT4)
in skeletal muscle, Akt phosphorylation, and AMPK phos-
phorylation in liver and/or muscle. In contrast, this treat-
ment reduced the expression level of phosphoenolpyruvate
carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase),
fatty acid synthase (FAS), and apolipoprotein C-III (apo C-
III) in liver. Overall, this work postulates that TS possesses
glucose- and lipid-lowering activities via a reduction of
hepatic glucose reduction involving reduced PEPCK and
G6Pase and a reduction of FAS and apo C-III, respectively. In
the paper entitled “Protein Fractions from Korean Mistletoe
(Viscum album coloratum) Extract Induce Insulin Secretion
from Pancreatic Beta Cells,” K.-W. Kim et al. show that V.
album coloratum extract (KME) stimulated insulin secretion
inRINm5F, a𝛽 cell line. Furthermore,DEAE fraction ofKME
extract, obtained from DEAE chromatography, increased the
mRNA level of insulin and PDX1. Both protein fractions,
lectin-free fraction and DEAE fraction of KME, could reduce
blood glucose in alloxan-treatedmice.This study implies that
KME can exert antidiabetic action via upregulation of insulin
production.
In human clinical studies, Lai and his colleagues (“Bidens
pilosa Formulation Improves Blood Glucose Homeostasis
andBeta-Cell Function inMen:APilot Study,”) reports a pilot
study of the antidiabetic herb, B. pilosa, in diabetic patients.
The authors first showed that single or combination use of
B. pilosa could significantly reduce fasting blood glucose and
glycosylated hemoglobin A1c (HbA1c) in diabetic subjects.
Consistently, B. pilosa increased fasting insulin. Moreover,
combination use of B. pilosa with other antidiabetic agents
had better glucose control than B. pilosa alone. The home-
ostatic model assessment (HOMA) data proposed that the
antidiabetic activity of B. pilosawas via preservation of 𝛽-cell
function.They also showed safety of the B. pilosa formulation
in healthy subjects.
In addition to original research articles, this special
issue also features review articles. A review entitled “Natu-
rally Occurring Anthraquinones: Chemistry andTherapeutic
Potential in Autoimmune Diabetes” describes a class of
naturally occurring anthraquinones (NOAQs) in relation to
type 1 diabetes from chemical, biological, pharmacological,
and clinical aspects. Another review by R. D. Umrani and K.
M. Paknikar, “Jasada Bhasma, a Zinc-BasedAyurvedic Prepa-
ration: Contemporary Evidence of Antidiabetic Activity
Inspires Development of a Nanomedicine,” summarizes the
importance of one Ayurvedic medicine, zinc-based bhasma,
on diabetes. The authors discuss the preparations of zinc-
containing bhasma in a nanoparticle size and their studies
in cells and animals. The zinc-containing bhasma might
act to delay the severity of diabetes and progression of its
complications. These review articles shed light on further
directions for CAM in diabetes and diabetic complications.
We anticipate that this special issue will be of interest to
the researchers/readers in the field of diabetes and drawmore
attention to the use of CAM-based therapies for diabetes and
the related complications.
Acknowledgments
We would like to thank the authors for their excellent
contributions and all the reviewers for their tremendous time
and efforts in assisting us.
Wen-Chin Yang
Cicero L. T. Chang
Cheng-Rui Li
Srinivas Nammi
William C. S. Cho
